Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03201718
Other study ID # P16-666
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 17, 2017
Est. completion date October 11, 2019

Study information

Verified date October 2020
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.


Recruitment information / eligibility

Status Completed
Enrollment 505
Est. completion date October 11, 2019
Est. primary completion date October 11, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Participants with type C hepatitis

- Participants prescribed Viekira/Exviera in accordance with approved local label

Exclusion Criteria:

- None

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Korea, Republic of Bucheon St. Mary's hospital /ID# 170782 Bucheon
Korea, Republic of Soon Chun Hyang University Hospital Bucheon /ID# 201803 Buncheon Gyeonggido
Korea, Republic of Dong-A University Hospital /ID# 167362 Busan Busan Gwang Yeogsi
Korea, Republic of Dongnam Institute of Radiologi /ID# 167721 Busan
Korea, Republic of Good Samsun Hospital /ID# 167365 Busan
Korea, Republic of Haeundae Paik Hospital /ID# 170767 Busan
Korea, Republic of Inje University Busan Paik Hospital /ID# 167392 Busan Gyeongsangbugdo
Korea, Republic of Kosin University Gospel Hosp /ID# 168797 Busan
Korea, Republic of Maryknoll Medical Center /ID# 167418 Busan
Korea, Republic of Pusan National University Hosp /ID# 167363 Busan Busan Gwang Yeogsi
Korea, Republic of Changwon Fatima Hospital /ID# 201664 Changwon Gyeongsangnamdo
Korea, Republic of Samsung Changwon Hospital /ID# 167732 Changwon
Korea, Republic of Dankook University Hospital /ID# 167730 Cheonan
Korea, Republic of Chuncheon Sacred Heart Hosp /ID# 167419 Chuncheon
Korea, Republic of Daegu Catholic University Med /ID# 167714 Daegu
Korea, Republic of Daegu Catholic University Med /ID# 168729 Daegu
Korea, Republic of Keimyung Univ Dongsan medical /ID# 168793 Daegu
Korea, Republic of Kim Jun Hwan Sok Internal Medi /ID# 168794 Daegu
Korea, Republic of Kyungpook National Univ Hosp /ID# 168731 Daegu Daegu Gwang Yeogsi
Korea, Republic of Kyungpook National University Chilgok Hospital /ID# 201804 Daegu Seoul Teugbyeolsi
Korea, Republic of Yeungnam University Med Ctr /ID# 167425 Daegu Daegu Gwang Yeogsi
Korea, Republic of The Catholic Univ. of Korea /ID# 167733 Daejeon
Korea, Republic of SMG-SNU Boramae Medical Center /ID# 201805 Dongjak-gu Seoul Teugbyeolsi
Korea, Republic of Dongguk University Ilsan Hosp /ID# 168795 Goyang
Korea, Republic of Myongji Hospital /ID# 170784 Goyang
Korea, Republic of National health insurance cooperation ilsan hospital /ID# 201806 Goyang Gyeonggido
Korea, Republic of CHA Gumi Medical Center /ID# 170783 Gumi
Korea, Republic of Chonnam National University Hospital /ID# 167423 Gwangju Jeonranamdo
Korea, Republic of Kwangju Christian Hospital /ID# 210823 Gwangju Jeonranamdo
Korea, Republic of Korea University Ansan Hosp /ID# 201661 Gyeonggi-do
Korea, Republic of Dongtan Sacred Heart Hospital /ID# 170759 Hwaseong
Korea, Republic of The Catholic University of Korea Incheon St.Mary's Hospital /ID# 170769 Incheon
Korea, Republic of Presbyterian Medical Center /ID# 167424 Jeonju
Korea, Republic of Kangbuk Samsung Hospital /ID# 168792 Jongno-Gu Seoul Teugbyeolsi
Korea, Republic of Chungnam National University Hospital /ID# 167724 Jung-gu Daejeon Gwang Yeogsi
Korea, Republic of Inha University Hospital /ID# 201802 Jung-gu Incheon Gwang Yeogsi
Korea, Republic of Bundang Jesaeng hospital /ID# 167725 Seongnam
Korea, Republic of CHA Bundang Medical Center /ID# 170757 Seongnam
Korea, Republic of Seoul National Univ Bundang ho /ID# 167394 Seongnam Gyeonggido
Korea, Republic of Asan Medical Center /ID# 167390 Seoul
Korea, Republic of Chung-Ang University Hostipal /ID# 167420 Seoul
Korea, Republic of Inje University Sanggye Paik H /ID# 167427 Seoul
Korea, Republic of Inje University Seoul Paik Hos /ID# 167426 Seoul
Korea, Republic of Konkuk University Medical Ctr /ID# 167723 Seoul Seoul Teugbyeolsi
Korea, Republic of Korea University Anam Hospital /ID# 167731 Seoul
Korea, Republic of Korea Universtiy Guro Hospital /ID# 167388 Seoul Seoul Teugbyeolsi
Korea, Republic of Samsung Medical Center /ID# 167722 Seoul Seoul Teugbyeolsi
Korea, Republic of Seoul National University Hospital /ID# 167364 Seoul
Korea, Republic of Seoul National University Hospital /ID# 167389 Seoul
Korea, Republic of Severance Hospital /ID# 167361 Seoul Seoul Teugbyeolsi
Korea, Republic of SoonChunHyang University Seoul /ID# 167711 Seoul
Korea, Republic of St. Carollo General Hospital /ID# 167712 Suncheon
Korea, Republic of St. Vincent's Hospital /ID# 201660 Suwon Gyeonggido
Korea, Republic of Ajou University Hospital /ID# 167729 Suwon-si Gyeonggido
Korea, Republic of Uijeongbu St. Mary's Hospital /ID# 168730 Uijeongbu
Korea, Republic of Ulsan University Hospital /ID# 168796 Ulsan
Korea, Republic of Wonju Severance Christian Hosp /ID# 167713 Wonju
Korea, Republic of Pusan National University Yang /ID# 167710 Yangsan-si
Korea, Republic of Yeosoo Hankook Hospital /ID# 168728 Yeosu

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) the lower limit of quantitation (LLOQ) SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [ 12 weeks after the last dose of study drug
Secondary Percentage of Participants With On-treatment Virologic Failure On-treatment virologic failure was defined as confirmed HCV RNA = LLOQ after HCV RNA < LLOQ during treatment; confirmed increase of > 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA = LLOQ at end of treatment with at least 6 weeks of treatment. Up to 24 weeks
Secondary Percentage of Participants With Post-treatment Relapse Post-treatment relapse defined as confirmed HCV RNA = LLOQ between end of treatment and 12 weeks after the last dose of study drugs among participants who complete treatment and with HCV RNA levels < LLOQ at the end of treatment From the end of treatment through 12 weeks after the last dose of study drug
See also
  Status Clinical Trial Phase
Completed NCT02487199 - Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease Phase 3
Completed NCT03235349 - Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection Phase 3
Completed NCT04577482 - Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Completed NCT03222583 - A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection Phase 3
Completed NCT02609659 - Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection Phase 3
Completed NCT04352309 - Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
Completed NCT04366973 - A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers
Completed NCT03069365 - A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment Phase 3
Completed NCT01754974 - Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C Phase 3
Withdrawn NCT01447394 - Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Phase 3
Completed NCT03067129 - A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection Phase 2/Phase 3
Completed NCT03219216 - A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection Phase 3
Completed NCT02517515 - ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection Phase 3
Completed NCT01616524 - Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 Phase 3
Completed NCT02966795 - A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection Phase 3
Completed NCT04189627 - A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
Completed NCT03341871 - Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
Recruiting NCT04214028 - A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
Completed NCT03212521 - Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 Phase 3
Active, not recruiting NCT04903626 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Phase 3

External Links